A detailed history of Invesco Ltd. transactions in Altimmune, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 30,743 shares of ALT stock, worth $232,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,743
Previous 27,757 10.76%
Holding current value
$232,724
Previous $282,000 27.66%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.91 - $10.23 $17,647 - $30,546
2,986 Added 10.76%
30,743 $204,000
Q1 2024

May 14, 2024

SELL
$8.22 - $13.81 $5.91 Million - $9.92 Million
-718,424 Reduced 96.28%
27,757 $282,000
Q4 2023

Feb 12, 2024

BUY
$2.14 - $11.62 $1.53 Million - $8.29 Million
713,152 Added 2159.17%
746,181 $8.39 Million
Q3 2023

Nov 13, 2023

BUY
$2.4 - $3.45 $11,894 - $17,098
4,956 Added 17.65%
33,029 $85,000
Q2 2023

Aug 11, 2023

BUY
$3.45 - $5.97 $96,851 - $167,595
28,073 New
28,073 $99,000
Q4 2022

Feb 13, 2023

BUY
$8.74 - $16.45 $3.72 Million - $7.01 Million
425,849 New
425,849 $7.01 Million
Q2 2022

Aug 15, 2022

SELL
$3.94 - $11.77 $48,532 - $144,982
-12,318 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $2,873 - $4,602
487 Added 4.12%
12,318 $75,000
Q4 2021

Feb 14, 2022

SELL
$8.69 - $12.48 $9,637 - $13,840
-1,109 Reduced 8.57%
11,831 $108,000
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $21,091 - $42,058
2,502 Added 23.97%
12,940 $147,000
Q2 2021

Aug 17, 2021

SELL
$9.85 - $16.46 $3.96 Million - $6.62 Million
-402,385 Reduced 97.47%
10,438 $103,000
Q1 2021

May 17, 2021

SELL
$12.71 - $24.31 $3.72 Million - $7.11 Million
-292,575 Reduced 41.48%
412,823 $5.83 Million
Q4 2020

Feb 16, 2021

BUY
$7.84 - $14.22 $2.11 Million - $3.83 Million
269,439 Added 61.8%
705,398 $7.96 Million
Q3 2020

Nov 16, 2020

BUY
$9.93 - $33.26 $2.05 Million - $6.86 Million
206,300 Added 89.83%
435,959 $5.75 Million
Q2 2020

Aug 14, 2020

BUY
$2.9 - $10.71 $666,011 - $2.46 Million
229,659 New
229,659 $2.46 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $371M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.